Skip to main content
Erschienen in: International Journal of Colorectal Disease 6/2019

08.04.2019 | Original Article

Impact and risk factors of non-adherence to 5-aminosalicylates in quiescent ulcerative colitis evaluated by an electronic management system

verfasst von: M. P. Ballester, D. Marti-Aguado, M. Fullana, M. M. Bosca-Watts, J. Tosca, E. Romero, A. Sanchez, P. Navarro-Cortes, R. Anton, F. Mora, M. Minguez

Erschienen in: International Journal of Colorectal Disease | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Background and objective

To determine the impact of non-adherence to 5-Aminosalicylates (5-ASA) on the risk of flares and to identify risk factors of non-adherence.

Methods

Observational, cohort study of ulcerative colitis (UC) patients in clinical remission at least 6 months on 5-ASA monotherapy maintenance prescribed by an electronic management program. Adherence was considered when 80% of the prescribed 5-ASA had been dispensed at the pharmacy. The study analyzed the existence and degree of 5-ASA adherence, disease course, UC phenotypic expression, and 5-ASA dose and regimen, and consumption of non-UC chronic drugs during 2-year follow-up.

Results

The study included 274 patients, 49% males with a median age of 38 (27–49) years old. Overall, 41% of patients were non-adherent to 5-ASA. Risk of flares was reduced in the adherent group (36% vs 54%; OR = 0,484; p = 0,004), mainly the mild ones (26% vs 38%; OR = 0,559; p = 0,031). Non-adherence was associated with younger age at diagnosis (32 (26–45) vs 41.5 (21–50), p = 0.000) and no-consumption of other chronic treatments (1.1 vs 2.1; OR = 1709; p = 0,048).

Conclusion

Non-adherence to 5-ASA evaluated by the pharmaceutical management system was at 41% with a higher risk of relapse. Younger patients and patients who do not receive non-UC chronic treatments showed lower adherence rate.
Literatur
1.
Zurück zum Zitat Hardbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, Kucharzik T, Molnár T, Raine T, Sebastian S, de Sousa HT, Dignass A, Carbonnel F, European Crohn’s and Colitis Organisation (ECCO) (2017) Third European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohn Colitis 11:769–784. https://doi.org/10.1093/ecco-jcc/jjx009 CrossRef Hardbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, Kucharzik T, Molnár T, Raine T, Sebastian S, de Sousa HT, Dignass A, Carbonnel F, European Crohn’s and Colitis Organisation (ECCO) (2017) Third European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohn Colitis 11:769–784. https://​doi.​org/​10.​1093/​ecco-jcc/​jjx009 CrossRef
5.
Zurück zum Zitat Velayos FS, Terdiman JP, Walsh JM (2005) Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 100:1345–1353CrossRefPubMed Velayos FS, Terdiman JP, Walsh JM (2005) Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 100:1345–1353CrossRefPubMed
9.
Zurück zum Zitat Kane S, Huo D, Aikens J, Hanauer S (2003) Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 114:39–43CrossRefPubMed Kane S, Huo D, Aikens J, Hanauer S (2003) Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 114:39–43CrossRefPubMed
10.
Zurück zum Zitat Kawakami A, Tanaka M, Nishigaki M, Naganuma M, Iwao Y, Hibi T, Sanada H, Yamamoto-Mitani N, Kazuma K (2013) Relationship between non-adherence to aminosalicylate medication and the risk of clinical relapse among Japanese patients with ulcerative colitis in clinical remission: a prospective cohort study. J Gastroenterol 48:1006–1015. https://doi.org/10.1007/s00535-012-0721-x CrossRefPubMed Kawakami A, Tanaka M, Nishigaki M, Naganuma M, Iwao Y, Hibi T, Sanada H, Yamamoto-Mitani N, Kazuma K (2013) Relationship between non-adherence to aminosalicylate medication and the risk of clinical relapse among Japanese patients with ulcerative colitis in clinical remission: a prospective cohort study. J Gastroenterol 48:1006–1015. https://​doi.​org/​10.​1007/​s00535-012-0721-x CrossRefPubMed
12.
Zurück zum Zitat Khan N, Abbas AM, Bazzano LA, Koleva YN, Krousel-Wood M (2012) Long-term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10-years retrospective cohort from the veterans affairs healthcare system. Aliment Pharmacol Ther 36:755–764. https://doi.org/10.1111/apt.12013 CrossRefPubMed Khan N, Abbas AM, Bazzano LA, Koleva YN, Krousel-Wood M (2012) Long-term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10-years retrospective cohort from the veterans affairs healthcare system. Aliment Pharmacol Ther 36:755–764. https://​doi.​org/​10.​1111/​apt.​12013 CrossRefPubMed
13.
Zurück zum Zitat Van Staa TP, Card T, Logan RF, Leufkens HG (2005) 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut 54:1573–1578CrossRefPubMedPubMedCentral Van Staa TP, Card T, Logan RF, Leufkens HG (2005) 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut 54:1573–1578CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Kane S, Shaya F (2008) Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci 53:1020–2024CrossRefPubMed Kane S, Shaya F (2008) Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci 53:1020–2024CrossRefPubMed
19.
Zurück zum Zitat Ediger JP, Walker JR, Graff L, Lix L, Clara I, Rawsthorne P, Rogala L, Miller N, McPhail C, Deering K, Bernstein CN (2007) Predictor of medication adherence in inflammatory bowel disease. Am J Gastroenterol 102(7):1417–1426CrossRefPubMed Ediger JP, Walker JR, Graff L, Lix L, Clara I, Rawsthorne P, Rogala L, Miller N, McPhail C, Deering K, Bernstein CN (2007) Predictor of medication adherence in inflammatory bowel disease. Am J Gastroenterol 102(7):1417–1426CrossRefPubMed
21.
Zurück zum Zitat Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K, Jewell DP, Karban A, Loftus EV Jr, Peña AS, Riddell RH, Sachar DB, Schreiber S, Steinhart AH, Targan SR, Vermeire S, Warren BF (2005) Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 19(Suppl):5A–36ACrossRefPubMed Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K, Jewell DP, Karban A, Loftus EV Jr, Peña AS, Riddell RH, Sachar DB, Schreiber S, Steinhart AH, Targan SR, Vermeire S, Warren BF (2005) Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 19(Suppl):5A–36ACrossRefPubMed
23.
Zurück zum Zitat Singh S, Proudfoot JA, Dulai PS, Jairath V, Fumery M, Xu R, Feagan BG, Sandborn WJ (2018) No benefit of concomitant 5-aminosalicylates in patients with ulcerative colitis escalated to biologic therapy: pooled analysis of individual participant data from clinical trials. Am J Gastroenterol. https://doi.org/10.1038/s41395-018-0144-2 Singh S, Proudfoot JA, Dulai PS, Jairath V, Fumery M, Xu R, Feagan BG, Sandborn WJ (2018) No benefit of concomitant 5-aminosalicylates in patients with ulcerative colitis escalated to biologic therapy: pooled analysis of individual participant data from clinical trials. Am J Gastroenterol. https://​doi.​org/​10.​1038/​s41395-018-0144-2
25.
Zurück zum Zitat Keil R, Keil R, Wasserbauer M, Zádorová Z, Kojecký V, Hlava Š, Št'ovíček J, Chudý J, Roznětinská M, Drábek J, Kubišová N, Lochmannová J (2018) Adherence, risk factors of non-adherence and patient's preferred treatment strategy of mesalazine in ulcerative colitis: multicentric observational study. Scand J Gastroenterol 53(4):459–465. https://doi.org/10.1080/00365521.2018.1451915 CrossRefPubMed Keil R, Keil R, Wasserbauer M, Zádorová Z, Kojecký V, Hlava Š, Št'ovíček J, Chudý J, Roznětinská M, Drábek J, Kubišová N, Lochmannová J (2018) Adherence, risk factors of non-adherence and patient's preferred treatment strategy of mesalazine in ulcerative colitis: multicentric observational study. Scand J Gastroenterol 53(4):459–465. https://​doi.​org/​10.​1080/​00365521.​2018.​1451915 CrossRefPubMed
Metadaten
Titel
Impact and risk factors of non-adherence to 5-aminosalicylates in quiescent ulcerative colitis evaluated by an electronic management system
verfasst von
M. P. Ballester
D. Marti-Aguado
M. Fullana
M. M. Bosca-Watts
J. Tosca
E. Romero
A. Sanchez
P. Navarro-Cortes
R. Anton
F. Mora
M. Minguez
Publikationsdatum
08.04.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
International Journal of Colorectal Disease / Ausgabe 6/2019
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-019-03271-9

Weitere Artikel der Ausgabe 6/2019

International Journal of Colorectal Disease 6/2019 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.